[go: up one dir, main page]

WO2009157884A2 - Dispositif d'application locale de médicament (ldad) - Google Patents

Dispositif d'application locale de médicament (ldad) Download PDF

Info

Publication number
WO2009157884A2
WO2009157884A2 PCT/TR2009/000079 TR2009000079W WO2009157884A2 WO 2009157884 A2 WO2009157884 A2 WO 2009157884A2 TR 2009000079 W TR2009000079 W TR 2009000079W WO 2009157884 A2 WO2009157884 A2 WO 2009157884A2
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
canal
drug
distal
balloons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2009/000079
Other languages
English (en)
Other versions
WO2009157884A3 (fr
Inventor
Erturk Genc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2009157884A2 publication Critical patent/WO2009157884A2/fr
Publication of WO2009157884A3 publication Critical patent/WO2009157884A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1011—Multiple balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1002—Balloon catheters characterised by balloon shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector

Definitions

  • This incentive is used for treatment of cancer etc. superficial pathological tissues and infections in the canals such as oesophagus, trachea, larynx, pharynx, nasal cavity, outer ear path, Eustachian canal, large intestines, rectum, urethra, penis, and vagina and cysts such as urinary bladder, lung, uterus, and stomach, and cavities such as maxillary sinus. It is applied intraoperatively to the canals and cysts inside that body that are inaccessible from outside through a clearance as in the formations that we have listed hereinabove. It can also be used to regress stenos in the cancers of the organs of the non-operable patients listed above, to extend their lifetime and to provide a more comfortable life.
  • superficial pathological tissues and infections in the canals such as oesophagus, trachea, larynx, pharynx, nasal cavity, outer ear path, Eustachian canal, large intestines, rect
  • chemosurgery agents used for treatment of cancer agents such as ionized argon gas used in the organ plasma technique, liquids used for thermodynamic treatment, liquid local haemostatics, antimicrobial drugs, antimycotic drugs used for treatment of resistant infections (candida oesophagitis, Barret oesophagus, chronic sinusitis etc.) and some drugs and stains used for endoscopic treatment and the drugs used to facilitate tissue healing can be applied on the application tract in this way. Drugs can be applied in aerosol form for sinuses. Present Known Condition of Local Drug Application Technique
  • drugs such as photosynthesizers, radiosynthesizers including the chemotherapeutical drugs used for cancer treatment are rather administered systemically. Locally, they are administered intraperitoneal, intraarterial, intrapleural, intratecal and intravesical.
  • cytotoxic drugs it is possible for a cytotoxic drug to penetrate into urethra and then to the kidney in intravesical applications, for instance, when applied with single balloon devices. As the tissue surface that the drug is contact increases, the quantity that proceeds to the systemic circulation will increase. Proportionally, the quantity of drug needed will increase (increasing cost). Chemotherapeuticals that proceed to the systemic circulation have significant reversible and irreversible effects.
  • thermochemotherapy agents cannot be applied on the aforesaid canals, cysts and cavities due to heat and as the dispersion of liquid is not restricted in a tract. Superiorities of LDAD to Single Balloon or Systemic Drug Application
  • Radiosynthesizers are applied locally and become more efficient in shorter time.
  • the administered drug can stay in the tract as long as it is wished. This means continuation of the efficiency of drug as long as it is wished. This can
  • the drug that becomes inefficient can be absorbed from the tract and new drug can be administered before removing the device out.
  • some microorganisms have to be under the influence of antimicrobial drugs for a certain time to vanish. This is achieved by
  • an antimicrobial drug can be administered successively.
  • LDAD In the endoluminal and mixed tumours of trachea that cause stenos, LDAD that is designed empty as the endotracheal canal (ref. Figure 8/9) serves as a
  • the presently known stents only function as stent, but cannot provide the function of local drug application, which is provided by LDAD.
  • Anaerobic microbes are destroyed with conventional methods, e.g. by means of systemic antibiotherapy.
  • anaerobes within canals, cysts and cavities can also be made with oxygen or liquid or antibiotics in aerosol form that are captured exactly in the relevant tract. pH of the tract can be changed to help this process.
  • acid agents may be administered for the microorganisms living in basic pH 13.
  • acid agents may be administered for the microorganisms living in basic pH 13.
  • the drug can only be applied on the organs such as bladder and uterus, the front of which is closed, in which case the urethra, kidneys, tubas and ovaries following these cysts are subject to adverse effects of the administered drugs. As the surface that the drug reaches increases, the
  • Double Balloon Interescopy system that includes a tube that contains scopy and a larger second tube that moves on in and one balloon at each end of both tubes does not ensure sealing between these two tube systems, it cannot restrict the drug locally and it is already a device that has been developed to make endoscopic inspection on the small intestines.
  • the device While administering the drug on one hand, the device will have to continually discharge the air on the other hand as there is no supplemental
  • the device is more of a lavage machine nature.
  • the device cannot be used in trachea, larynx applications made through general anesthesia since it has no canal to send the anesthetic gases to the lung.
  • LDAD has an appropriate canal (19) for these applications.
  • the device has no large canal such as the ventilation, anesthetic gas, nutrition and urine drainage canal (19) in our device to discharge the
  • Tube is fabricated rigid or flexible as full inside or in the form of canal according to the intended purpose and organ that it will be applied.
  • Balloons and tube are prepared at different diameters, thicknesses, sizes and forms according to age, gender and personal differences.
  • Balloons and tube will have the flexibility that will not irritate the tissue and that will adapt to the surrounding anatomic structure easily.
  • Tube is design in different ways according to the anatomy of the canal that it will be applied to (gradient, diameter and length of canal etc.) and its intended 245 function.
  • Distal end (1 1) is terminated in the form of U to facilitate proceeding and it is made longer than the distal edge (10) of the distal balloon Thus, any irritation does not occur on the tissues while proceeding. Edges at the end of the tube are rounded to prevent irritation. All surfaces are smooth and glazed.
  • Mouth of air pressure neutralizing canal (45) This is the starting 255 mouth of the air pressure neutralizing canal at the distal end of the tube
  • Proximal End of Tube (1) This is located outside the body.
  • Content a. Balloons inflating- deflating (main) holes: There is one hole at the beginning of the inflating - deflating canals of all balloons used in the
  • Balloons inflating - deflating (reserve) holes Reserve inflating- deflating canals of all balloons used in the system starts with a hole.
  • reserve holes are opened and balloon is deflated. They are in the form of a plug.
  • Small balloons of the balloons are the small balloons that are located behind each principal hole and useful for feeling the air pressure within the balloon. • Small balloon of the proximal balloon (23)
  • 295 drug is administered through an injector by means of the hole herein.
  • valve is brought to the OFF position when the drug administration process is ended. After the application, the valve is turned on again and the drug is discharged by retracting the injector piston through this inlet. This hole may serve as the mouth
  • Inlet end of fiberoptic system (72) This is the beginning of the fiberoptic system to monitor the drug application area (2) at the proximal end (1) of the tube.
  • Mouth of air discharge canal (37) This is the valve at the mouth of the air discharge canal (36) that ensures the discharge of the air in the area where the drug is applied while administering the drug. This is in 310 the form of a plug. The valve is turned off as the drug starts to get out.
  • Mouth (valve) of supplemental air discharge canal of the systems 315 containing support balloons (51) This is the mouth of the supplemental air discharge canal of the systems containing support balloons. This is in the form of a plug. 5.
  • Content of tube body a.
  • Main inflating-deflating canals There is available a separate 320 inflating- deflating canal for each balloon in the system.
  • Drug administration - discharge canal (39) The drug reaches to the drug application area (2) through this canal. When the process is ended, the drug 340 is discharged through this canal. This canal is wider in the devices considered to carry out lavage function. This may be used as the air discharge canal, d.
  • Outlet of drug administration - discharge canal (41) The drug (39) coming through the drug administration- discharge canal is discharged to the
  • Outlet hole of supplemental drug charge - discharge canal (47) This is 360 the hole which the canal in the area over the proximal edge (13) of the support balloon belonging to the supplemental drug charge-discharge canal (46) begins from.
  • Mouth (hole) of air discharge canal (37) This is the valve that is located at the beginning of the air discharge canal (36).
  • Inlet of air discharge canal (38) This is the hole through which the air in the drug application area (2) enters into the air discharge canal (36).
  • This 375 hole is located at the edge (3) of the distal end of the tube in the devices in which compression like a sandwich technique is used as shown in the figures 8 and 9.
  • Supplemental air discharge canal of the systems containing support balloons (49) This is the canal that discharges the air in the 380 second division formed by the support balloon (12).
  • Inlet hole of the supplemental air discharge canal of the systems containing support balloon (50) This is the hole through which the air in the drug application area (2) enters into the supplemental air discharge canal (49). This is located under the distal edge (14) of the support balloon
  • Shape of outer edges of the balloons (6) is formed according to the anatomy of the area.
  • the devices of which the drug application area (2) is at different length are selected according to the length of the lesion.
  • Proximal balloon (4) This is the balloon that is closest to outside the body. It
  • Distal balloon (5) This is the balloon that is distal to the canal mouth. Its function is to prevent the drug to go deeper, and hence enter into the systemic circulation. Furthermore, it prevents abortive use of the drug. Its function is
  • Proximal safety balloon (15) and distal safety balloon (16) In the event of a rupture or leakage on the distal (5) and proximal (4) balloons in very toxic drugs
  • Distal safety balloon (16) is located immediately behind the distal balloon (5) and the proximal safety balloon (15) is located immediately in front of the proximal balloon (4).
  • the proximal safety balloon In applications such as vagina, penis, urethra, external auditory canal, nasal cavity etc., the proximal safety balloon
  • balloon (15) is unnecessary as the drug will leave the body rapidly and easily even in the event of rupture of the proximal balloon (4).
  • Support balloon (12) In cases where the area to be applied is long or the tonus of tissues that constitute the canal is too much, support balloon (12) is placed at the intermediate section so that the adhesion of canal is prevented. In this case, there is
  • 425 will be supplemental drug administration- discharge canal outlet hole (47) and supplemental air discharge canal outlet hole (50) that will administer the drug and discharge the air in the area between the compartments in the tube body.
  • Filler balloon (17) They are placed at different heights and sides in the area where the drug is applied for positioning on the side of healthy tissue in order not
  • the outer edge (18) of the filler balloon may be in alignment 435 with the tissue contact edge (6) of the proximal balloon or may be more inside.
  • Filler balloon may surround the tube as in the figures 7 and 8.
  • Filler balloons are designed to be shaped according to the organ that they will be 440 used. For example, in the case of stomach cancer, it is designed to obstruct upper
  • Outer edge of filler balloon (18) This is the filler balloon's edge that is closest to or in contact with tissue. 445 7. Monitoring and Imaging:
  • Fiberoptic system (28) This system is used in order to observe the formations and developments in the drug application area (2).
  • Imaging system (29) This is the endoscopic system from the proximal end (1) of the tube to the distal end (11) in order to understand from where the
  • Inlet end of imaging system ( 71 ) This is the inlet at the proximal end (1) of the imaging system.
  • the approximate diameter of canal that will be reached through inflation is pre-defined and the amount of liquid to be administered can be pre-defined through the method of determining the cylinder volume except for the cases where filler balloons will be used.
  • the filler balloon is
  • the tube is made slippery with a drug that will not irritate the tissue, that will not have adverse reaction with the drugs to be administered and that will not cause infection or any undesired change on the lesion in order to facilitate its penetration.
  • the tube is advanced with proper manoeuvres within the canal through the endoscopic system (29). The process is stopped when the proximal edge (9) of the distal balloon passes by the distal edge of the lesion or infection area. It is now the turn of inflating the distal balloon (5).
  • the distal balloon (5) is started to be inflated. Tonus of the distal balloon is felt from the small balloon of the proximal end by the time and the inflation process continues. When sufficient tonus is obtained, the inflation process is ended. The same method is used for inflating all other balloons.
  • Proximal balloon (4) is inflated.
  • Proximal safety balloon (15), if any, is inflated.
  • the patient Before drug administration, the patient is positioned in the manner so that the drug accesses to the target tissue in the easiest manner by the gravity. It is positioned to avoid leakage in any case during the application process. For example, the patient lies on his/her sinus side where application is made during the application process in the event of sinus applications made
  • volume of the administered drug is noted. This will serve to understand whether there remains liquid in the canal or not after discharging the canal when the process will be terminated. Particularly, this fact will be important in cases where it is not desired to have toxic substances in the canal. Equality between the input and output liquid shows that there is no drug
  • Mouth of drug administration- discharge canal (40) is opened. It is ensured that the liquid is drained. The liquid is collected in a vessel with a degree.
  • the drug is tried to be aspired by installing an aspirator to the mouth of drug administration - discharge canal (40).
  • the local haemostatic agents in the form of liquid or pomade are administered to the area by means of the same method before deflating the balloons after discharging the drug.
  • Proximal safety balloon (15), if any, is deflated completely.
  • Proximal balloon (14) is deflated completely.
  • LDAD in the Figure 1 1 is used.
  • the distal balloon (5) is inflated in the lower bound of pharynx, immediately behind the ending area of lesion; the proximal
  • balloon (4) is inflated just in front of the upper bound of lesion, within the pharynx. If necessary, a filler balloon (17) may be inserted into the drug administration area (2). Ventilation, anesthetic gas, nutrition and urine drainage canal (19) in the middle of tube acts as a nutrition canal here.
  • the device administers drug in the applications of pharynx, nasopharynx, trachea and oesophagus on the one
  • the device in the figure 1 is used in the short-term applications, and the device in the figure 11 is used in the long-term applications.
  • the ventilation, anesthetic gas, nutrition and urine drainage canal (19) of the device shown in the figure 11 acts as
  • the distal balloon (5) is inflated in the pylorus area at the level of duodenum, and the proximal balloon (4) is inflated in the joint area of stomach- oesophagus at the
  • filler balloons (17) with a volume and shape that can cover the middle and upper section of stomach may be used; if the mass is in the upper section, filler balloons (17) that will occupy the lower and middle sections of the stomach may be used; and if the mass is in the middle section,
  • Duodenum application LDAD in the Figure 1 is used.
  • the distal balloon (5) is inflated in the pars horizontalis, and the proximal balloon (4) is inflated in the pylorus.
  • LDAD in the Figure 1 is used. If necessary, such devices with distal supplemental safety balloon (16), filler balloon (17) or support balloon (12) may also be used. In the case of irrigation using the device, the devices with wide administration- discharge canal (39) and air discharge canal (36) are preferred.
  • proximal (4) and proximal safety (15) balloons are to occlude the ositum by compressing the nasal wall of the sinus taken to the compression area (68) like a sandwich if the procedure is carried out from the nasal cavity, or to prevent the drug from leaking back from the
  • the devices in the figures 8 and 9 are used. These devices contain only proximal (4) and proximal safety (15) balloons.
  • Filler balloon (17) includes part or all of the tube circumference. In the case of
  • the filler balloon enclosing the tube is inflated in some degree so as not to contact with the walls of sinus in order to use fewer drugs. If the procedure is carried out surgically from the fossa canina, the devices in the figures 6 and 7 are used.
  • the distal balloon (5) is inflated inside of the nasal wall of sinus
  • the proximal balloon (4) is inflated inside of the side wall of sinus
  • the proximal safety balloon is inflated on the exterior surface of maxilla.
  • the distal balloon (5) occludes the ostiums and prevents the drug from passing to the nasal cavity
  • the proximal balloon (4) and proximal safety balloon compress the bone like a sandwich in the surgical procedure area and prevent the drug from leaking to the fossa canina area. If necessary, filler balloons
  • the device also acts as a stent in the respiratory system applications.
  • Distal balloon ( 5 ) is inflated in the choana dextra, and the proximal balloon (4) is inflated in the vestibulum nasi. 630 Nasopharynx Application
  • the proximal balloon (4) is inflated in the choana dextra, and the distal balloon (5) is inflated in the nasopharyngeal isthmus.
  • the lesion is taken to between distal (4) and proximal (5) balloons.
  • the ventilation 635 or anesthetic gas delivery is carried out from the ventilation, anesthetic gas, nutrition and urine drainage canal (19).
  • the device also acts as a stent during the application.
  • the device in figure 11 is used in the long-term application in order not to preclude the urine drainage.
  • the ventilation, anesthetic gas, nutrition and urine drainage canal (19) acts as a urine drainage canal.
  • the device also acts as a stent here.
  • the distal balloon (5) is inflated in the front line of prostate, and thus the prostate is prevented from being affected by the drug. This distal bound may further be brought forward according to the layout of lesion.
  • the proximal balloon (4) will be inflated in front of the front bound of the lesion. Where it is desired that the prostate is also affected, the distal balloon (5) is inflated in the bladder bottom.
  • the proximal balloon (4) is inflated at the beginning of urethra, and the distal balloon (5) is inflated in front of the bladder.
  • LDAD in the Figure 10 is used.
  • the distal balloon (5) is inflated on the top of
  • the device in the figure 11 is used in the long-term applications.
  • the distal balloon (5) is inflated in the section of ureter close to the kidney, and the proximal balloon (4) is inflated
  • the proximal balloon (4) is inflated just in front of the prostate, and the distal balloon (5) is inflated in the ostium uretra internum.
  • the proximal balloon (4) of device in the figure 1 is inflated in front of the cervix, and its distal balloon (5) is inflated so as to be in the uterus. If the lesions are in the upper section of uterus, the LDAD in the figure 9 is used. The drug is prevented from returning by inflating the proximal balloon in the cervix area, and inflating the proximal safety balloon at
  • both balloons (4, 15) are also inflated in front of the cervix and a full sealing toward the front is provided.
  • the device in the figure 5 is used in order that the distal end of tube (11) will not 675 damage the tympanic membrane.
  • the air pressure that occurs during the inflating of distal balloon is neutralized by means of the air pressure neutralizing canal (44).
  • the mouth of this canal, namely the air pressure neutralizing canal (45) in the proximal (1) and distal (11) ends of the tube is open.
  • Figure 1 - Main device including the proximal (4) and distal (5) balloons.
  • Figure 2 - Device including the support balloon (12).
  • Figure 3 Device including the proximal safety (15) and distal safety balloons (16).
  • Figure 5 Device of which inside is in the form of a canal and of which the distal edge of distal balloon (10) and the distal end of tube (11) are in alignment.
  • Figure 6 Device without a filler balloon (17) and with a distal balloon (5) and with a feature of compressing like a sandwich.
  • Figure 7 Device with a filler balloon (17) and a distal balloon (5) and a feature of 690 compressing like a sandwich.
  • Figure 8 Device with a filler balloon (17) and without a distal balloon (5) and with a feature of compressing like a sandwich.
  • Figure 9 Device without a filler balloon (17) and without a distal balloon (5) and with a feature of compressing like a sandwich.
  • Figure 11 Device of which middle section is in the form of a canal and including proximal (4) and distal (5) balloons. 700 Description of parts numbered in the figures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Selon l'invention, un LDAD capture principalement le médicament administré dans la zone située entre deux ballonnets par gonflage de deux ballonnets autour du tube de LDAD dans les canaux, vessies et cavités. Le médicament fait tout son effet intensivement et pendant la durée souhaitée uniquement entre deux ballonnets. Le médicament qui ne peut aller au delà des deux ballonnets n'a aucun effet indésirable ou inutile pour les autres tissus. Il est également sélectif dans la zone d'application de médicament (2) du fait de la présence du ballonnet de remplissage (17). Le dispositif peut être utilisé pour le traitement du cancer et le traitement d'infections. En cas de traitement d'infections, un médicament antimicrobien est également administré dans la zone, le pH et l'oxygénation de la zone sont également modifiés et il est possible d'attaquer des micro-organismes de trois façons différentes. Afin de tirer profit de l'effet synergique de l'oxygène sur certains antibiotiques, ils peuvent être administrés en même temps. Un quelconque dispositif creux fait également office d'endoprothèse vasculaire.
PCT/TR2009/000079 2008-06-27 2009-06-29 Dispositif d'application locale de médicament (ldad) Ceased WO2009157884A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2008/04721 2008-06-27
TR2008/04721A TR200804721A2 (tr) 2008-06-27 2008-06-27 Bölgesel ilaç uygulama cihazı ( bluc )

Publications (2)

Publication Number Publication Date
WO2009157884A2 true WO2009157884A2 (fr) 2009-12-30
WO2009157884A3 WO2009157884A3 (fr) 2010-02-25

Family

ID=41338899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2009/000079 Ceased WO2009157884A2 (fr) 2008-06-27 2009-06-29 Dispositif d'application locale de médicament (ldad)

Country Status (2)

Country Link
TR (1) TR200804721A2 (fr)
WO (1) WO2009157884A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018050165A1 (fr) * 2016-09-16 2018-03-22 David Spiggle Cathéter servant à administrer un fluide dans l'oreille moyenne
JP2021137459A (ja) * 2020-03-09 2021-09-16 テルモ株式会社 カテーテル及びその使用方法
WO2024141283A1 (fr) * 2022-12-30 2024-07-04 Auriventis Gmbh Cathéter auriculaire pour application d'un médicament
WO2024141284A1 (fr) * 2022-12-30 2024-07-04 Auriventis Gmbh Cathéter auriculaire amélioré pour appliquer un médicament

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2074304C (fr) * 1991-08-02 1996-11-26 Cyril J. Schweich, Jr. Catheter pour l'administration de medicaments
US5514092A (en) * 1994-08-08 1996-05-07 Schneider (Usa) Inc. Drug delivery and dilatation-drug delivery catheters in a rapid exchange configuration

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018050165A1 (fr) * 2016-09-16 2018-03-22 David Spiggle Cathéter servant à administrer un fluide dans l'oreille moyenne
CN109789298A (zh) * 2016-09-16 2019-05-21 大卫·斯皮格 用于将介质施加到中耳中的导管
CN109789298B (zh) * 2016-09-16 2022-05-17 德国宾格医疗技术股份有限公司 用于将介质施加到中耳中的导管
JP2021137459A (ja) * 2020-03-09 2021-09-16 テルモ株式会社 カテーテル及びその使用方法
JP7405652B2 (ja) 2020-03-09 2023-12-26 テルモ株式会社 カテーテル及びその使用方法
WO2024141283A1 (fr) * 2022-12-30 2024-07-04 Auriventis Gmbh Cathéter auriculaire pour application d'un médicament
WO2024141284A1 (fr) * 2022-12-30 2024-07-04 Auriventis Gmbh Cathéter auriculaire amélioré pour appliquer un médicament

Also Published As

Publication number Publication date
WO2009157884A3 (fr) 2010-02-25
TR200804721A2 (tr) 2009-02-23

Similar Documents

Publication Publication Date Title
KR101456108B1 (ko) 도뇨관
US8734314B2 (en) Method and kit for delivery of brachytherapy to a subject
US10898693B2 (en) Nasal delivery of agents with nested balloon catheter
US5007897A (en) Drug delivery catheter
CN203264017U (zh) 靶向扩张成形球囊导管
CN102123758A (zh) 使用者控制液体从膀胱排出的导尿管装置
RU84711U1 (ru) Назобилиарный катетер-дренаж
CN103656843A (zh) 靶向扩张成形球囊导管
US6423038B1 (en) Topical intra-uterine anesthesia device and method
RU2411918C1 (ru) Устройство для остановки носового кровотечения
AU2014348345A1 (en) Method of sinusitis treatment
WO2009157884A2 (fr) Dispositif d'application locale de médicament (ldad)
US20210236769A1 (en) Balloon catheter
JPH03258268A (ja) 気管内留置チューブ
CN223169796U (zh) 输卵管导管套件
RU2669052C1 (ru) Катетер для проведения электрофореза и введения лекарственных средств в барабанную полость
CN116531644A (zh) 一种精准定位施药导管、应用及其治疗系统
US12109136B2 (en) Devices and methods to treat and prevent diverticulitis
CN201076663Y (zh) 非自反气管导管
CN2098297U (zh) 医用多功能药囊导管
CN111888631A (zh) 用于结直肠梗阻的扩张装置
CN221557028U (zh) 一种鼓室咽鼓管药物释放引流装置
CN222384019U (zh) 一种人体腔道内药物释放用球囊导管
CN110025360A (zh) 一种腹腔镜胃部分切除手术用胃管
CN219070257U (zh) 一种外径可调式儿科扩肛器

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770502

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09770502

Country of ref document: EP

Kind code of ref document: A2